SCHEMBL1308669

SCHEMBL1308669

CCOC(=O)C1(CC2CC2)CCN(C(=O)C(Cc2ccc(OC)cc2)NC(=O)NCCc2c[nH]cn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.46
MEN1 O00255 5/20 0.46
POLB P06746 4/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MC4R P32245 3/20 0.39
ALDH1A1 P00352 4/20 0.39
MC5R P33032 1/20 0.39
MC3R P41968 1/20 0.39
MC1R Q01726 1/20 0.39
MAPK1 P28482 1/20 0.39
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PKM P14618 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2317164 0.94 MEN1 (0.41) KMT2AMEN1POLBHTTL3MBTL1
SCHEMBL1308853 0.92 MC4R (0.42) KMT2AMEN1POLBHTTL3MBTL1
SCHEMBL15016726 0.92 KMT2A (0.43) KMT2AMEN1HTTMC4RALDH1A1
SCHEMBL15704093 0.89 MC4R (0.39) KMT2AMEN1HTTMC4RALDH1A1
SCHEMBL1309007 0.88 MC4R (0.42) KMT2AHTTMC4RALDH1A1MC5R
SCHEMBL1307814 0.87 MC4R (0.43) HTTMC4RALDH1A1MC5RMC3R
SCHEMBL1307815 0.87 MC4R (0.43) HTTMC4RALDH1A1MC5RMC3R
SCHEMBL2315290 0.87 MC4R (0.43) HTTMC4RALDH1A1MC5RMC3R
SCHEMBL1310141 0.87 MC4R (0.43) HTTMC4RALDH1A1MC5RMC3R
SCHEMBL15016559 0.86 KMT2A (0.46) KMT2APOLBMC4RMC5RMC3R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2790692-B1 ASSOCIATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND OF A MC1R RECEPTOR AGONIST FOR TREATING AND/OR PREVENTING PIGMENTATION DISORDERS GALDERMA RES & DEV (FR) 2016-11-23 EP claimed
US-9364455-B2 Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-06-14 US claimed
US-20140371147-A1 COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-12-18 US claimed
US-8877968-B2 Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-11-04 US claimed
EP-2352728-B1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RES & DEV (FR) 2014-05-21 EP claimed
US-20110275657-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-11-10 US claimed
US-9364455-B2 Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-06-14 US disclosed
US-20140371147-A1 COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-12-18 US disclosed
US-8877968-B2 Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-11-04 US disclosed
EP-2352728-B1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RES & DEV (FR) 2014-05-21 EP disclosed
US-20120301458-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2012-11-29 US disclosed
WO-2012131090-A1 METHOD FOR TREATMENT OF XERODERMA PIGMENTOSUM GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-10-04 WO disclosed
US-20110275657-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-11-10 US disclosed
EP-2352728-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS Galderma Research & Development (FR) 2011-08-10 EP disclosed
WO-2010052255-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371147-A1 COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS MC1R, MC3R, MC5R KMT2A 2817/4885MEN1 1971/4885POLB 1192/4885
US-20120301458-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR P2RY12, P2RY11, P2RY2 KMT2A 4671/4885MEN1 4398/4885POLB 4082/4885
US-20110275657-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS MC1R, MC5R, MC3R KMT2A 2487/4885MEN1 274/4885POLB 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.